AndersonRPukettWDanaWNguyenTTheissJ and MatneyT. (1982, November). Risk of handling injectable antineoplastic agents. American Journal of Hospital Pharmacy, pp. 1881–1887.
2.
BrodyRSchottenfeldD and ReidA. (1977). Multiple primary cancer risk after therapy for Hodgkin's disease. Cancer, 40, pp. 1917–1926.
3.
BroggerA. (1974). Caffeine-induced enhancement of chromosome damage in human lymphocytes treated with methyl-methane-sulphonate, mitomycin C and x-rays. Mutation Research, 23, pp. 353–360.
4.
BrownM. (1981). Occupational Health Nursing. New York: Springer Publishing Company.
5.
CrudiC. (1980). A compounding dilemma: I've kept the drug sterile but have I contaminated myself?National IV Therapy Association, 3, p. 77.
6.
DeVitaV. (1982). Principle of Chemotherapy, Philadelphia: JB Lippincott, p. 153.
7.
DreisenSBodeyG and RodriquesV. (1975, August). Oral complications of cancer chemotherapy. Postgraduate Medicine, 2, pp. 75–82.
8.
EngelkingCH and SteeleNE. (1984, June). A model for pretreatment nursing assessment of patients receiving cancer chemotherapy. Cancer Nursing, pp. 203–212.
9.
FalckKGrohnPSorsaMVainioHHeinonenE and HolstiL. (1979, June 9). Mutagenicity in urine of nurses handling cytostatic drugs. Lancet, pp. 1250–1251.
10.
GrossJJohnsonBL and BertinoJR. Possible hazards of working with cytotoxic agents. Oncology Nursing Forum, pp. 10–12.
11.
HarrisonB. (1981, November). Developing guidelines for working with antineoplastic drugs. American Journal of Hospital Pharmacy, 38, pp. 1686–1693.
12.
JefferyLP. (1983, August). National Study Commission on Cytotoxic Exposure. Rhode Island Hospital Department of Pharmacy.
13.
KapadiaSKrauseJEllisLPanS and WaldN. (1980). Induced acute non-lymphocytic leukemia following long term chemotherapy. Cancer, 45, pp. 1315–1321.
14.
KnowlesR and VirdenJ. (1980, August 30). Handling of injectable antineoplastic agents. British Medical Journal, pp. 589–591.
15.
KirkorianJBurkeJRosenbergS and KaplanH. (1979, March 1). Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. New England Journal of Medicine, pp. 452–458.
16.
LadikCStoehrG and MaurerH. (1980, September). Precautionary measures in the preparation of antineoplastics. American Journal of Hospital Pharmacy, pp. 1184, 1186.
17.
NealAWaddenR and ChiouW. (1983). Exposure of hospital workers to airborne antineoplastic agents. American Journal of Hospital Pharmacy, 40, pp. 597–601.
18.
NorppaHScorsaMVainioHGrohnPHolstiL and NordmanE. (1980). Increased sister chromatic exchange frequencies in lymphocytes of nurses handling cytostatic drugs. Scandinavian Journal of Work and Environmental Health, pp. 299–301.
19.
ReichS. (1981, December). Antineoplastic agents as potential carcinogens: Are nurses and pharmacists at risk?Cancer Nursing, pp. 500–502.
20.
SotaniemiESutinenSArrantoASutinenSSotaniemiKLehtolaJ and PelkonenR. (1983). Liver damage in nurses handling cytostatic agents. Acta Medicine Scandinavian, 214, pp. 181–189.
21.
StaianoNGallelliJAdamsonR and ThrogeirssonS. (1981, March 14). Lack of mutagenic activity in urine from hospital pharmacists admixing antitumor drugs. Lancet, pp. 615–616.
22.
VainoH. (1982). Inhalation anesthetics, anticancer drugs and sterilants as chemical hazards in hospitals. Scandinavian Journal of Work and Environmental Health, pp. 94–107.
23.
VenittSCrofton-SleighCHuntJSpeechleyV and BriggsK. (1984, January 14). Monitoring exposure of nursing and pharmacy personnel to cytotoxic drugs: Urinary mutation assays and urinary platinum as markers of absorption. Lancet, pp. 74–77.
24.
WaksvikHKleppO and BroggerA. (1981, July/August). Chromosome analysis of nurses handling cytostatic agents. Cancer Treatment Reports, 65, pp. 607–610.
25.
WilsonJ and SolimandoD. (1981, May). Antineoplastics: A safety hazard?American Journal of Hospital Pharmacy, p. 624.
26.
ZimmermanPLarsenRBarkleyE and Gallelli. (1981, November). Recommendations for the safe handling of injectable antineoplastic drug products. American Journal of Hospital Pharmacy, 38, pp. 1693–1695.
